BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. Expert Opin Drug Saf. 2017;16:651-672. [PMID: 28471314 DOI: 10.1080/14740338.2017.1325869] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Kadir Dokmeci A, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Ooka Y, Yokosuka O, Sarin SK, Omata M. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol Int 2019;13:649-61. [PMID: 31541423 DOI: 10.1007/s12072-019-09988-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
2 Bartenschlager R, Baumert TF, Bukh J, Houghton M, Lemon SM, Lindenbach BD, Lohmann V, Moradpour D, Pietschmann T, Rice CM, Thimme R, Wakita T. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Res 2018;248:53-62. [PMID: 29477639 DOI: 10.1016/j.virusres.2018.02.016] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 20.5] [Reference Citation Analysis]
3 Kida T, Umemura A, Kaneshita S, Sagawa R, Inoue T, Toyama S, Wada M, Kohno M, Oda R, Inaba T, Itoh Y, Kawahito Y. Effectiveness and safety of chronic hepatitis C treatment with direct-acting antivirals in patients with rheumatic diseases: A case-series. Mod Rheumatol 2020;30:1009-15. [PMID: 31625432 DOI: 10.1080/14397595.2019.1682787] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Lesnova EI, Masalova OV, Permyakova KY, Kozlov VV, Nikolaeva TN, Pronin AV, Valuev-Elliston VT, Ivanov AV, Kushch AA. Difluoromethylornithine (DFMO), an Inhibitor of Polyamine Biosynthesis, and Antioxidant N-Acetylcysteine Potentiate Immune Response in Mice to the Recombinant Hepatitis C Virus NS5B Protein. Int J Mol Sci 2021;22:6892. [PMID: 34206987 DOI: 10.3390/ijms22136892] [Reference Citation Analysis]
5 Lu MY, Chen CT, Shih YL, Tsai PC, Hsieh MH, Huang CF, Yeh ML, Huang CI, Wang SC, Tsai YS, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML, Chang WY. Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. Sci Rep 2021;11:8554. [PMID: 33879825 DOI: 10.1038/s41598-021-87975-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tucci A, Rizza S, Cocchis D, Martini S, Romagnoli R, Marzano A. Early and Late Hepatitis B Reactivation After IFN- or DAA-based Therapy of Recurrent Hepatitis C in Anti-HBc-positive Liver Transplant Recipients. Transplantation 2018;102:e354-5. [PMID: 29757904 DOI: 10.1097/TP.0000000000002241] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Guss D, Sherigar J, Mohanty SR. Management of Hepatitis C: A Practical Primer for Nurses. Gastroenterol Nurs 2020;43:22-7. [PMID: 31913958 DOI: 10.1097/SGA.0000000000000430] [Reference Citation Analysis]
8 Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H. Present and Future Therapies for Chronic Hepatitis B. Adv Exp Med Biol. 2020;1179:137-186. [PMID: 31741336 DOI: 10.1007/978-981-13-9151-4_6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
9 Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chen JJ, Yu ML. Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals. Sci Rep 2018;8:15058. [PMID: 30305682 DOI: 10.1038/s41598-018-33448-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
10 Ponti ML, Comitini F, Murgia D, Ganga R, Canu R, Dessì C, Foschini ML, Leoni G, Morittu M, Perra M, Pilia MP, Casini MR, Zappu A, Origa R. Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major. Dig Liver Dis 2019;51:561-7. [PMID: 30658940 DOI: 10.1016/j.dld.2018.12.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Liu Y, Maya S, Ploss A. Animal Models of Hepatitis B Virus Infection-Success, Challenges, and Future Directions. Viruses 2021;13:777. [PMID: 33924793 DOI: 10.3390/v13050777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Italian Association for the Study of the Liver (AISF). AISF position paper on HCV in immunocompromised patients. Dig Liver Dis 2019;51:10-23. [PMID: 30366813 DOI: 10.1016/j.dld.2018.09.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Yeh ML, Huang CI, Huang CF, Hsieh MH, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Kuo PL, Dai CY, Yu ML, Chuang WL. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. J Infect Dis 2019;219:1224-33. [PMID: 30452671 DOI: 10.1093/infdis/jiy648] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
14 Zarębska-Michaluk D, Flisiak R, Flisiak-Jackiewicz M. Management of hepatitis B and hepatitis C coinfection: an expert review. Expert Rev Anti Infect Ther 2020;18:1033-44. [PMID: 32579414 DOI: 10.1080/14787210.2020.1776112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Guss D, Sherigar J, Rosen P, Mohanty SR. Diagnosis and Management of Hepatitis C Infection in Primary Care Settings. J Gen Intern Med. 2018;33:551-557. [PMID: 29352420 DOI: 10.1007/s11606-017-4280-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
16 Naderi N, Masoudi G, Behnava B, Alavian SM, Sari S, Anvar A, Azizi Saraji A, Namvar A, Bolhassani A. Detection of Occult Hepatitis B Virus Among Iranian HCV-Infected Patients with Hemophilia Treated with Direct-Acting Antiviral Agents. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.83337] [Reference Citation Analysis]
17 Hsieh MH, Yu ML. Reply to "Rescue for interferon failures in HCV genotype 1/HBV dually infection". J Formos Med Assoc 2018;117:861-2. [PMID: 30041996 DOI: 10.1016/j.jfma.2018.06.016] [Reference Citation Analysis]
18 Kulkarni AV, Duvvuru NR. Management of hepatitis B and C in special population. World J Gastroenterol 2021; 27(40): 6861-6873 [PMID: 34790011 DOI: 10.3748/wjg.v27.i40.6861] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Phinius BB, Anderson M, Bokete R, Mbangiwa T, Choga WT, Baruti K, Makhema J, Musonda R, Blackard JT, Essex M, Moyo S, Marlink R, Gaseitsiwe S. Incidence of hepatitis B virus infection among human immunodeficiency virus-infected treatment naïve adults in Botswana. Medicine (Baltimore) 2020;99:e19341. [PMID: 32118769 DOI: 10.1097/MD.0000000000019341] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Brochado-Kith Ó, Martínez I, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A, Ángeles Jiménez-Sousa M, Resino S. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients. Front Immunol 2021;12:723196. [PMID: 34497613 DOI: 10.3389/fimmu.2021.723196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Del Bello A, Abravanel F, Alric L, Lavayssiere L, Lhomme S, Bellière J, Izopet J, Kamar N. No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents. Transpl Infect Dis 2019;21:e13093. [PMID: 30972874 DOI: 10.1111/tid.13093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Yahya G, Hashem Mohamed N, Pijuan J, Seleem NM, Mosbah R, Hess S, Abdelmoaty AA, Almeer R, Abdel-Daim MM, Shulaywih Alshaman H, Juraiby I, Metwally K, Storchova Z. Profiling the physiological pitfalls of anti-hepatitis C direct-acting agents in budding yeast. Microb Biotechnol 2021. [PMID: 34378349 DOI: 10.1111/1751-7915.13904] [Reference Citation Analysis]
23 Mavilia MG, Wu GY. HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation. J Clin Transl Hepatol 2018;6:296-305. [PMID: 30271742 DOI: 10.14218/JCTH.2018.00016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 5.8] [Reference Citation Analysis]
24 Kanda T, Nirei K, Matsumoto N, Higuchi T, Nakamura H, Yamagami H, Matsuoka S, Moriyama M. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World J Gastroenterol 2017; 23(46): 8120-8127 [PMID: 29290649 DOI: 10.3748/wjg.v23.i46.8120] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Imazeki F, Moriyama M, Kato N. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget. 2018;9:11631-11637. [PMID: 29545925 DOI: 10.18632/oncotarget.24391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
26 Liu X, Duan X, Holmes JA, Li W, Lee SH, Tu Z, Zhu C, Salloum S, Lidofsky A, Schaefer EA, Cai D, Li S, Wang H, Huang Y, Zhao Y, Yu ML, Xu Z, Chen L, Hong J, Lin W, Chung RT. A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6. Hepatology 2019;69:1004-19. [PMID: 30199576 DOI: 10.1002/hep.30266] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
27 Holmes JA, Carlton-Smith C, Kim AY, Dumas EO, Brown J, Gustafson JL, Lauer GM, Silva ST, Robidoux M, Kvistad D, Alatrakchi N, Tonnerre P, Cohen DE, Zhang H, Shulman NS, Chung RT. Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection. J Viral Hepat 2019;26:362-72. [PMID: 30450781 DOI: 10.1111/jvh.13041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
28 Habashy NH, Abu-serie MM. Major royal-jelly protein 2 and its isoform X1 are two novel safe inhibitors for hepatitis C and B viral entry and replication. International Journal of Biological Macromolecules 2019;141:1072-87. [DOI: 10.1016/j.ijbiomac.2019.09.080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
29 Liang PC, Chen KY, Huang CH, Chang K, Lu PL, Yeh ML, Huang CF, Huang CI, Hsieh MH, Dai CY, Lin ZY, Chen SC, Chuang WL, Chen YH, Huang JF, Yu ML. Viral Interference Between Dengue Virus and Hepatitis C Virus Infections. Open Forum Infect Dis 2020;7:ofaa272. [PMID: 32875000 DOI: 10.1093/ofid/ofaa272] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Preda CM, Popescu CP, Baicus C, Constantinescu I, Oproiu A, Voiosu T, Diculescu M, Negreanu L, Gheorghe L, Sporea I, Trifan A, Ceausu E, Proca D, Manuc M. Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin. J Viral Hepat 2018;25:834-41. [PMID: 29397016 DOI: 10.1111/jvh.12872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, Rodriguez de Lope C, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. Journal of Hepatology 2019;70:874-84. [DOI: 10.1016/j.jhep.2019.01.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
32 Poola S, Sanaka S, Sewell K, Tillmann HL. Hepatitis B surface antibody titres and hepatitis B reactivation with direct-acting antiviral therapy for hepatitis C. J Viral Hepat 2021;28:373-82. [PMID: 33047433 DOI: 10.1111/jvh.13421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Wu Q, Li Z, Liu Q. An important role of SREBP-1 in HBV and HCV co-replication inhibition by PTEN. Virology 2018;520:94-102. [PMID: 29803738 DOI: 10.1016/j.virol.2018.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Prenner A, Blum R, Beltraminelli H, Stirnimann G, Borradori L. Subacute cutaneous lupus erythematosus triggered by an antiviral treatment combination for hepatitis C virus infection. J Eur Acad Dermatol Venereol 2018;33. [DOI: 10.1111/jdv.15330] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]